Navigation Links
A new target in acute myeloid leukemia
Date:7/16/2012

Acute myeloid leukemia, a common leukemia in adults, is characterized by aberrant proliferation of cancerous bone marrow cells. Activating mutations in a protein receptor known as FLT3 receptor are among the most prevalent mutations observed in acute myeloid leukemias. FLT3 mutants are thought to activate several signaling pathways that contribute to cancer development. Dr. Daniel Tenen and colleagues from Harvard University in Boston discovered a new pathway activated by FLT3 mutation. Their results show that cyclin dependent kinase 1 (CDK1), a critical regulator of cell division is activated in FLT3 mutated leukemias, leading to the activation of downstream gene transcription. Most importantly, they demonstrate that inhibiting CDK1 activity promotes differentiation of cells from patient-derived peripheral blood samples. As clinical trials with CDK1 inhibitors are ongoing, their data strongly suggest that therapies targeting the CDK1 pathway may be efficacious for acute myeloid leukemias with FLT3 mutation, especially in patients resistant to FLT3 inhibitor therapies.


'/>"/>
Contact: Sarah Jackson
press_releases@the-jci.org
Journal of Clinical Investigation
Source:Eurekalert

Page: 1

Related medicine news :

1. Targeted therapeutics for colon cancer to be presented at AACR meeting
2. First targeted nanomedicine to enter human clinical studies
3. SMART heart eases heart ache, targets cardiac patients emotional well-being
4. Target set on cancer gene MCL1
5. Scientists tailor cell surface targeting system to hit organelle ZIP codes
6. IBN discovers human neural stem cells with tumor targeting ability
7. A closer look at PARP-1 reveals potential new drug targets
8. Highly targeted irradiation as good as whole breast radiotherapy in early stage cancer
9. Breathing during radiotherapy - how to hit the treatment target without causing collateral damage
10. Scientists identify new target to battle rheumatoid arthritis
11. Scientists identify possible drug target for acute pancreatitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... ... 24, 2017 , ... symplrTM, a leading provider of software ... Kyle Allain has joined the company as Vice President and General Manager of ... payor and managed care solutions. , A seasoned executive with more than ...
(Date:4/24/2017)... ... April 24, 2017 , ... Rod Burkett, CEO of Gardant Management ... , Rod has been at the forefront of Gardant since it was founded in ... has overseen the opening of more than 40 new senior living communities. With his ...
(Date:4/24/2017)... ... April 24, 2017 , ... Labs often perform ... difficult for lab operators and management to assess these processes with a critical ... or unnecessary actions. , Created with the help of both internal and ...
(Date:4/24/2017)... ... April 24, 2017 , ... “Learning to Use Your SPIRITUAL COMPASS ... “Learning to Use Your SPIRITUAL COMPASS To Navigate Life Issues” is the creation of ... Chairman of the Board of Directors for CONTACT USA, and former member of the ...
(Date:4/24/2017)... Greensboro, NC and Seattle, WA (PRWEB) , ... ... ... currently utilized by 75+ leading lifestyle brands, work wear distributors and International relief ... diseases they can carry. The company also offers lifestyle and work wear collections ...
Breaking Medicine News(10 mins):
(Date:4/18/2017)... -- Viverae ® , a leader in workplace wellness ... ® Watson Campaign Automation, implementing behavioral messaging within ... personalized experience. Through digital engagement, the platform prompts members ... time. The enhanced experience drives engagement by focusing on ... are in their journey to health. ...
(Date:4/18/2017)... BLOOMINGTON, Minn. , April 18, ... IMMY ) ("Imprimis"), an ophthalmology-focused pharmaceutical company, and ... today announced the signing of a three-year exclusive ... will deploy a dedicated sales team to introduce ... U.S., primarily focused in 13 states in the ...
(Date:4/18/2017)... , April 18, 2017  Spero Therapeutics, LLC, ... the treatment of bacterial infections, will present preclinical data ... treatment of multidrug resistant (MDR) Gram-negative infections at the ... (ECCMID) April 22-25, 2017 in Vienna, Austria ... ...
Breaking Medicine Technology: